17 February 2020
Oncode Oncology Bridge Fund announces two Entrepreneurs in Residence
The Oncode Oncology Bridge Fund, launched by Oncode BV, is proud to announce the appointment of two Entrepreneurs in Residence (EIR’s). Dr. Markwin Velders (click for bio) brings over 25 years of research experience in the field of tumor immunology and over 18 years of management experience in biotechnology companies. Dr. Allard Kaptein (click for bio) is the Managing Director of Genase Therapeutics. Prior to that, he was co-founder of Acerta Pharma, spinning out the covalent BTK inhibitor series from MSD into Acerta Pharma.
17 February 2020
Oncode Institute appoints Chris De Jonghe as its new Valorization Director
Oncode Institute today announced that its Supervisory Board has appointed Chris De Jonghe as Valorization Director. Chris will start at Oncode Institute on May 4th and assumes her role as Valorization Director and all responsibilities on June 1st. Angus Livingstone, Oncode’s founding Valorization Director will stay with Oncode Institute until May 31st.
11 February 2020
Five Oncode Investigators win the first Ammodo Science Award for groundbreaking research
The winners of this award are the group behind the research project Guardians and Caretakers of the Genome based at the Erasmus MC and the research group Social Educational Neuroscience Amsterdam (SENSA) of the Vrije Universiteit Amsterdam. They each receive a cash prize of 1.2 million euros which they will use to explore new areas of research. Oncode Investigators Jurgen Marteijn, Wim Vermeulen, Roland Kanaar, Jan Hoeijmakers and Miao-Ping Chien are part of the Erasmus MC research project.
3 February 2020
World cancer day: the importance of patient engagement within cancer research
- Open article for English - 4 februari is het wereldkankerdag. Erica van Wuijtswinkel, patiëntvertegenwoordiger bij de Raad van Toezicht van Oncode Institute, legt uit waarom patiëntenparticipatie zo belangrijk is binnen kankeronderzoek. Ze bespreekt ook hoe zij haar rol binnen Oncode Institute invult en hoe Oncode patiëntenparticipatie heeft ingebed in de organisatie.
26 January 2020
Oncode researchers gain access to Organoid technology thanks to collaboration with KNAW
Thanks to an agreement between the Royal Netherlands Academy of Arts and Sciences (KNAW) and Oncode Institute, the organoid technology will become available to all 800+ cancer researchers that are part of Oncode. The KNAW collaborates with its institutional partner UMC Utrecht on organoid technology. Thanks to this agreement with Oncode, researchers receive a license to conduct research on organoids for the first time in the Netherlands.
23 January 2020
Venom-producing snake organoids developed in the lab
Researchers from the group of Oncode Investigator Hans Clevers, together with Oncode Investigators Anne Rios, Alexander van Oudenaarden and many others, have developed a method to grow snake venom gland cells as organoids. These lab-grown mini glands produce and secrete active toxins found in snake venom. Snake venom gland organoids can be grown from multiple species and maintained in the lab indefinitely. This new technology holds great promise to reduce the devastating impact and exploit the secrets of snake venom. The results of this research were published in the scientific journal Cell on the 23rd of January.
20 January 2020
Some subtypes of gastric/oesophageal adenocarcinoma responsive to immunotherapy
Interview with medical oncologist and Oncode Investigator Dr Sarah Derks. Gastric and oesophageal adenocarcinomas are a heterogeneous group, so it should come as no surprise that not all subtypes of gastric and oesophageal adenocarcinoma respond equally well to immunotherapy. Sarah explains why tumours that test positive for the Epstein-Barr virus and tumours with microsatellite instability are particularly responsive to immune checkpoint inhibitors.
17 December 2019
EU invests 10 million euro in unlocking technologies for key research in structural biology
To enable researchers from European institutes to extend innovative structural biology research, the EU has invested 10 million euro to iNEXT-Discovery, through its Horizon 2020 program.
10 December 2019
Oncode Investigators Elzo de Wit and Ruben van Boxtel receive ERC Grant
Oncode Institute is proud to announce that Oncode Investigators Elzo de Wit (Netherlands Cancer Institute) and Ruben van Boxtel (Princess Máxima Center) both receive the ERC Consolidator Grant. The ERC Consolidator Grants are awarded to outstanding researchers with at least seven and up to twelve years of experience after PhD, and a scientific track record showing great promise.
29 November 2019
Researchers explain the added value of Oncode Institute
At this year's Oncode-CGC Annual conference, we took the time to speak with some of our Oncode Investigators. In this video, they explain the value that Oncode adds to their research, collaboration opportinuties and valorization success.
29 November 2019
Oncode Institute invests 4 million euros in new technology for cancer research in the Netherlands
Oncode Institute invests 4 million euros in unique, state-of-the-art technology for cancer research. Five projects have been awarded within the Infrastructure & Technologies Programme. These technologies will not only become available for the twelve institutes that are affiliated with Oncode Institute but will also be made available to the wider research community in the Netherlands.
28 November 2019
Biotech Wednesday: Joining forces to outsmart cancer – new frontiers in cell therapy
United by a desire to bring new cell therapies to patients, Oncode Institute and HollandBIO brought together academia, life sciences companies, clinicians and other relevant stakeholders at this first of its kind event.
Scroll for more